17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[(3'-indolyl)acetamido]morphinan

ID: ALA3319612

Chembl Id: CHEMBL3319612

PubChem CID: 118709685

Max Phase: Preclinical

Molecular Formula: C29H31N3O4

Molecular Weight: 485.58

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2ccccc12

Standard InChI:  InChI=1S/C29H31N3O4/c33-22-8-7-17-13-23-29(35)10-9-21(31-27(34)19-14-30-20-4-2-1-3-18(19)20)26-28(29,24(17)25(22)36-26)11-12-32(23)15-16-5-6-16/h1-4,7-8,14,16,21,23,26,30,33,35H,5-6,9-13,15H2,(H,31,34)/t21-,23-,26+,28+,29-/m1/s1

Standard InChI Key:  LVHHPBVYXLNRRX-BJPCFZSKSA-N

Alternative Forms

  1. Parent:

    ALA3319612

    ---

Associated Targets(Human)

OPRK1 Tclin Opioid receptors; delta & kappa (935 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Tclin Opioid receptors; mu & kappa (822 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 485.58Molecular Weight (Monoisotopic): 485.2315AlogP: 3.24#Rotatable Bonds: 4
Polar Surface Area: 97.82Molecular Species: BASEHBA: 5HBD: 4
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 10.29CX Basic pKa: 9.51CX LogP: 2.47CX LogD: 0.65
Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.46Np Likeness Score: 0.76

References

1. Le Naour M, Lunzer MM, Powers MD, Kalyuzhny AE, Benneyworth MA, Thomas MJ, Portoghese PS..  (2014)  Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.,  57  (15): [PMID:24978316] [10.1021/jm500159d]

Source